|
Activation of human and zebrafish PXRs by pregnane steroids and related compounds |
||||||
| Cmp. # |
Compound |
hPXR Activity |
hPXR Efficacy |
zfPXR Activity |
zfPXR Efficacy |
Toxicity |
|
|
||||||
| PR1 |
5β-Pregnan-3α,20α-diol (5β-pregnanediol) |
5.29 |
0.34 |
None |
100 |
|
| PR2 |
5β-Pregnan-3,20-dione (5β-pregnanedione) |
5.59 |
0.97 |
6.08 |
0.85 |
None |
| PR3 |
4-Pregnen-11β,21-diol-3,20-dione (corticosterone) |
5.00 |
0.54 |
None |
None |
|
| PR4 |
4-Pregnen-17,21-diol-3,20-dione (cortexolone) |
4.64 |
0.49 |
None |
None |
|
| PR5 |
4-Pregnen-11β,21-diol-3,18,20-trione (aldosterone) |
4.26 |
0.21 |
None |
None |
|
| PR6 |
4-Pregnen-17,21-diol-3,11,20-trione (cortisone) |
4.16 |
0.28 |
None |
200 |
|
| PR7 |
4-Pregnen-3,20-dione (progesterone) |
4.83 |
0.57 |
None |
200 |
|
| PR8 |
4-Pregnen-17-ol-3,20-dione |
4.75 |
0.7 |
None |
None |
|
| PR9 |
4-Pregnen-21-ol-3,20-dione (cortexone) |
5.61 |
0.3 |
None |
200 |
|
| PR10 |
4-Pregnen-3β,17,21-triol-3,20-dione (cortisol) |
4.32 |
0.66 |
None |
None |
|
| PR11 |
5-Pregnen-3β,17-diol-20-one |
4.47 |
0.36 |
None |
None |
|
| PR12 |
5-Pregnen-3β-diol-20-one (pregnenolone) |
5.64 |
1.26 |
6.32 |
2.05 |
None |
| PR13 |
5-Pregnen-16α-cyano-3β-ol-20-one |
None |
None |
None |
||
| PR14 |
5α-Pregnan-3α-ol-20-one (allopregnanolone) |
5.38 |
0.46 |
5.40 |
0.30 |
None |
| PR15 |
5α-Pregnan-3α,20α-diol (allopregnanediol) |
4.28 |
0.16 |
4.58 |
0.29 |
None |
| PR16 |
5β-Pregnan-3α,20α-diol-3-glucosiduronate (pregnanediol glucuconide) |
4.26 |
0.17 |
4.78 |
1.42 |
None |
| PR17 |
5β-Pregnan-3α,11β,17,20α-21-pentol (cortol) |
4.33 |
0.83 |
3.95 |
0.98 |
200 |
| PR18 |
5β-Pregnan-3α,17,20α-21-tetrol-11-one (cortolone) |
4.35 |
0.72 |
4.34 |
0.25 |
200 |
| PR19 |
5β-Pregnan-3α,17,21-triol-11,20-dione |
4.28 |
0.8 |
4.43 |
0.33 |
None |
| PR20 |
5α-Pregnan-3α,11β,21-triol-20-one |
4.90 |
0.26 |
None |
None |
|
| PR21 |
4-Pregnen-17α,20β-diol-3,20-dione |
None |
None |
200 |
||
| PR22 |
4-Pregnen-20β-ol-3,20-dione-17α-sulfate |
5.73 |
0.66 |
None |
None |
|
| PR23 |
5β-Pregnan-3α,20β-diol |
5.42 |
0.49 |
5.95 |
0.25 |
None |
| PR24 |
5β-Pregnan-3α,11β,17,21-tetrol-20-one |
4.33 |
0.73 |
3.94 |
0.11 |
None |
| PR25 |
5β-Pregnan-3α-ol-20-one |
4.98 |
0.55 |
6.64 |
1.22 |
100 |
| PR26 |
5-Pregnen-20-one-3β-sulfate |
None |
4.95 |
0.23 |
None |
|
| PR27 |
4-Estren-17α-ethynyl-18-homo-17β-ol-3-one (levonorgestrel) |
5.37 |
0.35 |
6.00 |
0.86 |
None |
| PR28 |
4-Estren-17α-ethynyl-17β-ol-3-one (norethindrone) |
4.59 |
0.32 |
5.85 |
0.40 |
None |
| PR29 |
1,4-Pregnadien-9α-fluoro-16α-methyl-11β,17,21-triol-3,20-dione (dexamethasone) |
4.39 |
0.83 |
None |
None |
|
|
Activities are in -log(EC50), with EC50 in molar units for the activation of human or zebrafish PXR. Efficacy is relative to 10 μM rifampicin (human PXR) or 20 μM 5α-androstan-3α-ol (zebrafish PXR) which are assigned an efficacy of 1.0. Toxicity is the lowest concentration in micromolar that produced significant toxicity in the HepG2 cells. | ||||||
Ekins et al. BMC Evolutionary Biology 2008 8:103 doi:10.1186/1471-2148-8-103 |
||||||